颈动脉内膜切除术在颈动脉狭窄外科治疗中仍具成本效益
该研究基于CREST、VQI监测项目及本地成本数据,用Markov模型比较经颈动脉血运重建(TCAR)、颈动脉内膜切除术(CEA)和经股动脉颈动脉支架置入术(TFCAS)治疗症状性与无症状性颈动脉狭窄的终身成本与效果。结果显示TCAR相对CEA的增量成本效果比为160,642美元/QALY,超过100,000美元/QALY阈值;CEA在80%的模型迭代中被优选,仍是最具成本效益的治疗。
要点
- 当前成本与结局下,TCAR未达到替代CEA成为颈动脉狭窄主要治疗方式的传统成本效益阈值。
- TFCAS因围手术期卒中风险较高,成本更高且效果更差,是最不具成本效益的策略。
- 若TCAR卒中风险低于0.9%或手术成本降低约2000美元,则可能具有经济性。
核心结论
- 基于当前成本与结局,TCAR未达到替代CEA作为颈动脉狭窄主要治疗方式的传统成本效益阈值。
- CEA仍是颈动脉血运重建最具成本效益的治疗。
- TFCAS是颈动脉血运重建中最不具成本效益的策略。
研究设计与样本
- 采用Markov状态转换模型,整合CREST试验、血管质量倡议监测项目及本地成本数据。
- 比较TCAR、CEA和TFCAS治疗症状性与无症状性颈动脉狭窄的终身成本(美元)与效果(QALYs)。
- 模型假设起始年龄69岁,成本效益可接受阈值为100,000美元/QALY,并进行了敏感性分析。
主要发现
- 基础案例中,TCAR相对CEA的增量成本效果比为160,642美元/QALY,高于100,000美元/QALY阈值。
- TFCAS比其他策略更昂贵且效果更差,主要归因于更高的围手术期卒中风险。
- 单因素敏感性分析中,若TCAR卒中风险低于0.9%(基础案例风险1.4%),则在其当前手术成本下相对CEA具有经济性。
- 若TCAR手术成本降低约2000美元(基础案例成本15,182美元),则也具有经济性。
- 概率敏感性分析中,在100,000美元/QALY阈值下,CEA在80%的模型迭代中被优选,TCAR在19%中被优选。
关键数值与推荐
- 成本效益可接受阈值为100,000美元/QALY。
- TCAR相对CEA的增量成本效果比为160,642美元/QALY。
- TCAR基础案例卒中风险为1.4%,基础案例手术成本为15,182美元。
- TCAR卒中风险低于0.9%时,在当前手术成本下相对CEA具有经济性。
- TCAR手术成本降低约2000美元时,具有经济性。
临床怎么用
- 当前证据支持CEA作为颈动脉狭窄血运重建最具成本效益的首选治疗。
- TCAR应限于特定患者,尤其是那些因CEA而处于高生理和解剖风险的患者。
- 若TCAR成本降低或卒中风险优化至更低水平,可考虑其成本效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Transcarotid arterial revascularization (TCAR) has gained popularity as an alternative to carotid endarterectomy (CEA) and transfemoral carotid artery stenting (TFCAS), potentially combining the benefits of a minimally invasive approach with a lower risk of procedural stroke compared with TFCAS. Emerging evidence shows TCAR to have excellent perioperative outcomes. However, the cost-effectiveness of TCAR is not well-understood. METHODS: Incorporating data from Carotid Revascularization Endarterectomy vs Stenting Trial (CREST), the Vascular Quality Initiative Surveillance Project, and local cost data, we compared the cost-effectiveness of these three treatment modalities (TFCAS, CEA, and TCAR) for both symptomatic and asymptomatic carotid stenosis using a Markov state-transition model to quantify lifetime costs in United States dollars and effectiveness in quality-adjusted life-years (QALYs). We accounted for perioperative stroke and myocardial infarction, as well as long-term risks of stroke and restenosis. Based on CREST, we assumed a start age of 69 years and a cost-effectiveness acceptability threshold of $100,000/QALYs gained. Sensitivity analyses were performed. RESULTS: In the base-case scenario, TCAR cost $160,642/QALY gained compared with CEA, greater than the frequently cited $100,000/QALY gained threshold. TFCAS was more expensive and less effective than other strategies, largely due to a greater periprocedural stroke risk. In one-way sensitivity analysis, if TCAR stroke risk was <0.9% (base-case risk, 1.4%), than it was economically favorable compared with CEA at its current procedural cost. Alternatively, if TCAR procedural costs were reduced by approximately $2000 (base-case cost, $15,182), it would also become economically favorable. In a probabilistic sensitivity analysis, varying all parameters simultaneously over distributions, CEA was favored in 80% of model iterations at $100,000/QALY, with TCAR favored in 19%. CONCLUSIONS: At current cost and outcomes, TCAR does not meet a traditional cost-effectiveness threshold to replace CEA as the primary treatment modality for carotid stenosis. TFCAS is the least cost-effective strategy for carotid revascularization. Given these observations, TCAR should be limited to select patients, specifically those at high physiologic and anatomic risk from CEA. However, TCAR can become cost-effective if its cost is reduced. Given the current outcomes and cost, CEA remains the most cost-effective treatment for carotid revascularization.
引用
- Sridharan ND, Chaer RA, Smith K, et al. Carotid endarterectomy remains cost-effective for the surgical management of carotid stenosis. J Vasc Surg. 2021. PMID: 34634417. doi:10.1016/j.jvs.2021.09.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。